Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
Our USP is our real-time Nurse Practitioner (NP) approval before every single treatment
In June 2024, Semaglutide was approved for weight management in China under the brand Novo Nordisk, launching in November and generating DKK 686 million in Q1 2025
Retatrutide: Triple Receptor Activation Retatrutide activates three distinct hormone receptors simultaneously
GLP-1 is the naturally occurring agonist for GLP-1 receptors
Additionally, L-carnitine supports heart health and immune function by facilitating efficient energy supply to these vital systems
(2024, April 23)
US$ 22.50
US$ 23.32
US$ 21.58
US$ 22.03
US$ 25.06
US$ 20.80
US$ 29.73
US$ 26.38
US$ 29.59
US$ 28.90
